PMO Launches New Suboxone ® Medication AssistedTreatment Plus…

July 6, 2017

PMO Care announces implementation of Suboxone and Vivitrol Medication Assisted Treatment in conjunction with on-site counseling for…(PRWeb February 27, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10470251.htm (Source: PRWeb: Medical Pharmaceuticals)

Read the full article →

Jennifer Serrentino, M.D. Recently Launches a Blog Post Discussing the…

July 6, 2017

Well known local psychiatrist, Jennifer Serrentino, M.D., recently discusses the Suboxone controversy on her blog.(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Local-Port-Jefferson/Psychiatrist-Jennifer-Ser/prweb10636625.htm (Source: PRWeb: Medical Pharmaceuticals)

Read the full article →

Novel Opioid Dependence Pill Gets Patients' Thumbs-UpNovel Opioid Dependence Pill Gets Patients' Thumbs-Up

July 6, 2017

Compared with buprenorphine-naloxone sublingual film to treat opioid dependence, a sublingual menthol-flavored tablet has a preferred taste and comparable dissolve time. Medscape Medical News (Source: Medscape Today Headlines)

Read the full article →

Not Otherwise Specified: Anxiety & the Work of Dr. Robert Hudak

July 6, 2017

Southwest Pennsylvania National Alliance on Mental Illness (NAMI) held its annual conference at the beginning of April, and one of their afternoon breakout workshop presenters was Dr. Robert Hudak, assistant professor of psychiatry at Western Psychiatric Institute & Clinic, University of Pittsburgh. “Pathways to Hope: Shaping a Positive Future in Uncertain Times” was the conference […]

Read the full article →

Orexo starts patient dosing in Phase III study of opioid dependence drug

July 6, 2017

Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

FDA OKs New Formula for Addiction Drug

July 6, 2017

(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)

Read the full article →

Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) – new on RxList

July 6, 2017

(Source: RxList – New and Updated Drug Monographs)

Read the full article →

Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence

July 6, 2017

Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence. (Source: Drug Development Technology)

Read the full article →

Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning – Häkkinen M, Heikman P, Ojanperä I.

July 6, 2017

Buprenorphine (BPN) medication for opioid maintenance treatment in Finland consists predominantly of buprenorphine-naloxone (BNX). Both BPN and BNX are associated with diversion, abuse and non-medically supervised use worldwide. Our purpose was to estimate… (Source: SafetyLit: All (Unduplicated))

Read the full article →

Advertising Drugs to Addicts

July 6, 2017

A glut of information about prescription drugs makes it easy for addicts to get their fix from doctors. But worst of all, celebrities are now the pushers.read more (Source: Psychology Today Addiction Center) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% […]

Read the full article →

← Previous Entries

Next Entries →